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Introduction
•

•

•

Heart Failure (HF) is an abnormal clinical
condition involving impaired cardiac
pumping which results in characteristic
pathophysiologic changes related to
vasoconstriction and fluid retention
(Lewis, Dirksen, Heitkemper, & Butcher,
2011).
In most nations, HF has become a major
health problem with increasing
incidence. Currently, about 5.1 million
people in the United States are living
with heart failure. This equates to an
estimated $32 billion dollars each year
in national healthcare costs (Alan et al.,
2013).
I have chosen HF as my topic of choice,
mainly due to its prevalence in the
patient population that I serve. I
currently practice on an intermediate
unit where most patients suffer from
multiple comorbidities including some
form of heart failure. What I find most
fascinating about HF is the multiple
ways the human body attempts to
compensate for impaired cardiac
pumping and the clinical symptoms
associated with its disease process. HF
can influence a multitude of body
systems including the sympathetic
nervous system, kidney, immune and
pulmonary systems.

Underlying Pathophysiology
•

•
•
•

•

•

•

•

Neurohormonal Responses: The Renin-Angiotensin-Aldosterone System (RAAS)
When the kidney senses a decrease in perfusion, the renin–angiotensin-aldosterone
system (RAAS) is called into action. Angiotensin II is the primary effector hormone
secreted in response to physiological stimuli and is formed from its precursor,
angiotensinogen, by two enzymatic cleavages (Shearer & Struthers, 2013).
Angiotensinogen, released by the liver, is converted to angiotensin I by the action of
renin. Angiotensin I is then cleaved by angiotensin converting enzyme (ACE) from the
lungs to angiotensin II. Circulating angiotensin II promotes aldosterone secretion from
the adrenal cortex which increases water and sodium reabsorption. This leads to a
boost in intravascular fluid volume, and enhanced cardiac preload. It also causes
systemic vasoconstriction, increasing vascular resistance and cardiac afterload (Shearer
& Struthers, 2013).
Activation of the SNS and the neurohormonal response lead to elevated levels of
norepinephrine, angiotensin II, aldosterone, endothelin, and proinflammatory
cytokines. Together these factors result in an increase in cardiac workload, myocardial
dysfunction, and eventual ventricular remodeling (Lewis et al., 2011).

•

•

Clinical presentation of HF will
depend on the patient’s severity of
HF and particular pattern of disease.
Common manifestations of HF include
fatigue, dyspnea, exercise
intolerance, and fluid retention,
which may lead to pulmonary and
peripheral edema symptoms such as
adventitious lung sounds and weight
gain (Nicholson, 2014).
Signs and symptoms of advanced HF
consist of progressive exertional
dyspnea, paroxysmal nocturnal
dyspnea, orthopnea, fatigability, loss
of appetite, abdominal bloating, and
nausea or vomiting.

•

•

Significance of Pathophysiology

•

•

•

As the heart begins to fail the body’s metabolic demands, several compensatory
mechanisms are activated to maintain adequate tissue perfusion and cardiac output.
The main compensatory mechanisms include the sympathetic nervous system (SNS)
activation, neurohormonal responses, and cardiac remodeling.
Sympathetic Nervous System (SNS) Activation
Baroreceptors respond to a diminished CO and low BP by stimulating the SNS.
Activation of SNS promotes the maintenance of cardiovascular homeostasis by
inducing positive chronotropic and inotropic effects in the heart (increasing HR and
myocardial contractility), as well as increased peripheral arterial vasoconstriction
(Souda-Pinto, Ferreira-Pinto, Santos, Leite-Moreira, 2014).
Initially these compensatory changes improves CO, however over time these factors
act in detrimental fashion by increasing the heart’s need for oxygen and the
workload of the already failing heart (Lewis et al., 2011). Arterial vasoconstriction
increases CO by causing an increase in preload; however this leads to a higher
afterload pressure and increase of venous return thus creating additional ventricular
strain on the already volume overloaded heart.
Overactivation of the SNS is an important pathophysiological factor in HF. Although it
may first be an adaptive response, chronic adrenergic overactivation is considered
detrimental in the long run because it promotes cardiac remodeling and subsequent
dysfunction (Andersen, Andersen, de Man, & Nielsen-Kudsk, 2015).

•

Medication treatment focuses to
improve cardiac pump function,
augment fluid removal, and enhance
tissue perfusion. These goals are
achieved through the use of ACE
inhibitors, diuretics, and beta blocker
medications.
ACE inhibitors impede the neurohormal
response of the RAAS system thus
preventing systemic vasoconstriction
and water retention. Angiotensin
receptor blockers (ARBs) also inhibit the
RAAS system and can be utilized in
patients who cannot tolerate ACE
inhibitors.
Diuretics are used to decrease
intravascular volume. The reduction in
venous return reduces preload and
allows the overfilled LV to contract more
efficiently and improve CO. The increase
in left ventricular function, decreases
pulmonary vascular pressures, and
improves gas exchange. Hydralazine and
nitroglycerin are additional medications
that cause systemic vasodilation and a
reduction in afterload and preload, thus
eliminating some ventricular strain.
Beta-adrenergic blockers directly block
the negative effects of the SNS on the
failing heart such as increased HR and
systemic vasoconstriction. A reduction
in HR and systemic pressure allows
increased cardiac perfusion and lower
pressures to overcome during
contraction.
This medication list is not all-inclusive as
medication therapies should be tailored
to each patient. Additionally, new
medication and surgical therapies are
being discovered every day.

•

Implications for
nursing care
•

•

The primary cause of right-sided
heart failure is left-sided heart
failure. As previously mentioned, leftsided heart failure results in
pulmonary congestion and pulmonary
hypertension. Eventually this increase
in pulmonary pressure causes rightsided hypertrophy and failure. Rightsided failure causes a backup of blood
into the right atrium and venous
circulation. The major syndrome of
RV failure is volume overload and
fluid retention in the systemic
circulation, including peripheral
edema, jugular venous distention,
and ascites (Guglin & Verma, 2012).

•

Signs & Symptoms
•

Implications for
nursing care (cont.)

Significance of Pathophysiology (cont.)

HF is caused by any interference with the normal mechanisms of cardiac output
(CO). CO is dependent on preload, afterload, and myocardial contractility.
Accordingly, some origins of HF include CAD, cardiomyopathy, valvular disorders, MI,
dysrhythmias, HTN, and pulmonary disorders (Piepoli & Crisafulli, 2014).
Collectively these causes increase the workload of the ventricles, resulting in a
decompensated condition that leads to decreased myocardial function and an
impaired ability of the heart to maintain adequate CO.
HF is classified as systolic or diastolic.
Systolic HF is the most common cause of heart failure and results from the inability
of the ventricles to contract and pump blood. Systolic failure is a result of impaired
contractile function which can be caused by increased afterload due to HTN, MI,
cardiomyopathies, and valvular disorders. The left ventricle (LV) loses the ability to
generate enough pressure to eject blood forward through the aorta and over time
the LV becomes dilated, thin-walled, and hypertrophied (Lewis et al., 2011). The
hallmark of systolic dysfunction is a decrease in the left ventricular ejection fraction.
Diastolic Failure is an impaired ability of the ventricles to relax and fill with blood
during diastole. Decreased filling of the ventricles leads to decreased stroke volume
and CO. Diastolic failure is characterized by high filling pressures due to stiff or
noncompliant ventricles. This results in venous backflow in both the pulmonary and
systemic vascular systems (Komamura, 2013). The diagnosis of diastolic failure is
made on the basis of the presence of pulmonary congestion, pulmonary
hypertension, ventricular hypertrophy, and a normal EF (Lewis et al., 2011).

•

•

•
•

Cardiac Remodeling
Another compensatory mechanism of the heart (in efforts to maintain adequate CO) is
ventricular remodeling. Left ventricle (LV) remodeling involves changes in cavity size,
wall thickness, mass, and shape; all of which reflect adaptations to myocardial injury
and alterations in LV load (Ky et al., 2012).
Dilation is an enlargement of the chambers of the heart and occurs when pressure in
the heart chambers is elevated overtime. The muscle fibers of the heart stretch to
accommodate blood volumes in the heart at the end of diastole. At first this added
stretch leads to increase in contraction force (Frank-Starling Law), but eventually this
mechanism becomes inadequate because the elastic elements of the muscle fibers are
overstretched and can no longer contract effectively, thereby decreasing CO (Lewis et
al., 2011).
During chronic HF, the cardiac muscle adapts to volume overload and strain by
increasing cardiac muscle mass and cardiac wall thickness. This is called hypertrophy.
Hypertrophy further increases the contractile power of the muscle fibers causing a
short-term increase in tissue perfusion and CO. However, the hypertrophic heart
muscle has poor contractility, and requires more oxygen to perform work (Piepoli, &
Crisafulli, 2014).
Types of Heart Failure: Left-sided Failure vs. Right-sided Failure
HF usually manifests as biventricular failure, however one side may fail while the other
side continues to function normally for a period of time.
Left-sided heart failure is most common and results from left ventricular dysfunction
which prevents normal blood flow through the aorta and to the body. This causes blood
to back up into the left atrium and into the pulmonary veins. The increased pulmonary
pressure causes fluid extravasation from capillary beds into the interstitium and then
the alveoli, which presents clinically as pulmonary congestion and edema (Lewis et al.,
2011).

•

•

The main goals in treatment of HF is to
treat the underlying cause, maximize
CO, improve ventricular function,
provide treatment to alleviate
symptoms, improve quality of life, and
improve mortality and morbidity.
However, these goals can only be
achieved if both the patient and
caregiver and both understanding of
the patient’s plan of care. Patient’s
and caregivers require education
about heart failure to develop the
staff-patient relationship and improve
treatment concordance (Nicholson,
2014). Education empowers patients,
increases successful self-management,
and decreases rates of hospitalization.
Lifestyle modifications such as diet,
exercise, and smoking cessation
should be discussed.
Patients should also be taught that
good control of comorbid conditions
such as diabetes, high cholesterol, and
kidney disease improves cardiac
outcomes (Nicholson, 2014).
Education of early warning signs such
as weight gain and respiratory distress
should also be addressed.
Medications are the mainstay of heart
failure treatment. Medications can
relieve symptoms, reduce
hospitalizations, shorten length of stay
and improve quality of life and
prognosis (Nicholson, 2014). Again,
treatments such as medications only
work if the clinician and patient both
understand the treatment plan and
then carry it out together.

•

•

Conclusions
•

Current treatment for HF involves
lifestyle changes, patient education,
disease-modifying and symptomcontrolling medications.
Unfortunately, none of these
treatment methods provide a cure for
HF, but only make symptoms more
manageable and slow disease
progression. Because of this, it is of
paramount importance for both
patient and provider to understand
and adhere to education and
treatment plans. Only by working
together can therapeutic goals be
achieved and quality of life sustained.
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